From in vitro fertilization (IVF) to menopause: Physiologic hormone replacement adapted from donor egg IVF may be our best option for hormone therapy

Fertility and Sterility

Volumn 80, Issue 3, 2003, Pages 485-487

  De Ziegler, Dominique ^a   Meldrum, David R ^b  

^a Groupement Hospitalier de l'Ouest Lemanique   (Switzerland)

^b Reproductive Partners Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE; PROGESTERONE;

BLOOD CLOTTING DISORDER; CANCER RISK; CLINICAL PROTOCOL; DONOR; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; FERTILIZATION IN VITRO; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; OOCYTE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0042232348     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(03)00995-6     Document Type: Note

References (16)

1. de Ziegler D., Ferriani R., Moraes L.A., Bulletti C. Vaginal progesterone in menopause Crinone 4% in cyclical and constant combined regimens. Hum Reprod. 15:2000;149-158.
2. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 288:2002;321-333.
3. Alkjaersig N., Fletcher A.P., de Ziegler D., Steingold K.A., Meldrum D.R., Judd H.L. Blood coagulation in postmenopausal women given estrogen treatment comparison of transdermal and oral administration. J Lab Clin Med. 111:1988;224-228.
4. de Ziegler D. Is the liver a target organ for estrogen? Sitruck-Ware R., Utian W. The menopause and replacement therapy, facts and controversies. 1991;201-215 Marcel Deckker, New York.
5. Chetkowski R.J., Meldrum D.R., Steingold K.A., Randle D., Lu J.K., Eggena P., et al. Biologic effects of transdermal estradiol. N Engl J Med. 314:1986;1615-1620.
6. Bourgain C., Devroey P., Van Waesberghe L., Smitz J., Van Steirteghem A.C. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod. 5:1990;537-543.
7. Fanchin R., de Ziegler D., Bergeron C., Righini C., Torrisi C., Frydman R. Transvaginal administration of progesterone. Obstet Gynecol. 90:1997;396-401.
8. Cicinelli E., de Ziegler D. Transvaginal progesterone evidence for a new functional "portal system" flowing from the vagina to the uterus. Hum Reprod Update. 5:1999;365-372.
9. Cicinelli E., de Ziegler D., Galantino P., Pinto V., Barba B., Morgese S., et al. Twice a week transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women a 1-year prospective study. Am J Obstet Gynecol. 187:2002;556-560.
10. Adams M.R., Register T.C., Golden D.L., Wagner J.D., Williams J.K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Thromb Vasc Biol. 17:1997;217-221.
11. Miyagawa K., Rosch J., Stanczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 3:1997;324-327.
12. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S., et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys lack of an effect of added progesterone. Arteriosclerosis. 10:1990;1051-1057.
13. Williams J.K., Honore E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of artherosclerotic arteries in cynomolgus monkeys. J Am Coll Cardiol. 24:1994;1757-1761.
14. Rosano G.M., Webb C.M., Chierchia S., Morgani G.L., Gabraele M., Sarrel P.M., et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 36:2000;2154-2159.
15. Newcomb P.A., Titus-Ernstoff L., Egan K.M., Trentham-Dietz A., Baron J.A., Storer B.E., et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 11:2002;593-600.
16. Breast cancer and hormone replacement therapy. Lancet. 350:1997;1047-1059.